Azitra (NYSEAMERICAN:AZTR) Trading Down 5.1%

Azitra, Inc. (NYSEAMERICAN:AZTR) shares dropped 5.1% during trading on Thursday . The company traded as low as $0.18 and last traded at $0.19. Approximately 607,320 shares traded hands during mid-day trading, an increase of 18% from the average daily volume of 513,998 shares. The stock had previously closed at $0.20.

Azitra Stock Performance

The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.01.

Insider Activity

In other news, CEO Francisco D. Salva purchased 333,300 shares of the company’s stock in a transaction dated Tuesday, February 13th. The stock was bought at an average cost of $0.30 per share, for a total transaction of $99,990.00. Following the purchase, the chief executive officer now owns 338,300 shares of the company’s stock, valued at $101,490. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders bought 399,200 shares of company stock worth $115,476.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AZTR. Citadel Advisors LLC bought a new position in Azitra during the 2nd quarter worth $57,000. Warberg Asset Management LLC grew its holdings in Azitra by 20.7% during the 3rd quarter. Warberg Asset Management LLC now owns 35,000 shares of the company’s stock worth $52,000 after acquiring an additional 6,000 shares during the period. Finally, Knollwood Investment Advisory LLC acquired a new stake in Azitra during the 3rd quarter worth about $62,000. 11.16% of the stock is owned by institutional investors.

About Azitra

Azitra, Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S.